Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 and Everolimus in Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
NCT03070301Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2017
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in Neuroendocrine Neoplasm (NEN), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03070301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070301.